- Ondansetron hydrochloride
- Drug Entry
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation and use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis 7.
- Accession Number
- Ondansetron HCl / Ondansetron hydrochloride anhydrous
- CAS Number
- Average: 329.83
- Chemical Formula
- InChI Key
- IUPAC Name
- 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one hydrochloride
- Predicted Properties
Property Value Source Water Solubility 0.248 mg/mL ALOGPS logP 2.56 ALOGPS logP 2.35 ChemAxon logS -3.1 ALOGPS pKa (Strongest Acidic) 15.39 ChemAxon pKa (Strongest Basic) 7.34 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 39.82 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 86.78 m3·mol-1 ChemAxon Polarizability 33.16 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon